Skip to main content
Premium Trial:

Request an Annual Quote

Isis to Gain Almost $4M from Alnylam s Deal with Novartis

NEW YORK, Sept. 12 (GenomeWeb News) - Isis Pharmaceuticals expects nearly $4 million in payments from Alnylam Pharmaceuticals following Alnylam's recent deal with Novartis, the Carlsbad, Calif.-based company said today.

 

Isissaid it is entitled to a portion of the upfront payments and equity investment from Novartis as part of its 2004 partnership with Alnylam. It might also receive milestone and royalty payments on drugs which utilize technology it licensed to Alnylam.

 

Under the 2004 agreement, Isislicensed over 150 patents to Alnylam, including the "Crooke" patents that cover mechanisms of RNase-dependent antisense activity and chemically modified oligonucleotides. In exchange, Isisobtained a technology access fee, participation in fees for Alnylam's partnering programs, and downstream milestone and royalty payments.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.